Concentration of Opioid-Related Industry Payments in Opioid Crisis Areas

Lee, Austin J.; Bandari, Jathin; Macleod, Liam C.; Davies, Ben; Jacobs, Bruce L.

doi:10.1007/s11606-018-4700-7

Cited by 4 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this reason, they have been recommended for patients experiencing chronic pain for whom NSAIDs or acetaminophen are contraindicated (4). All these reasons coupled with aggressive marketing campaigns contributed to the dramatic increases in opioid prescriptions worldwide (2,8–18). However, concern about the devastating potential for opioid misuse among chronic pain patients has come to the forefront in the past decade (13,19–21).…”

Section: Introductionmentioning

confidence: 99%

Is There Any Role for Opioids in the Management of Knee and Hip Osteoarthritis? A Systematic Review and Meta‐Analysis

Osani

Lohmander

Bannuru

2021

Arthritis Care & Research

View full text Add to dashboard Cite

Objective Opioids have long been prescribed for chronic pain conditions, including osteoarthritis (OA). However, there is little information about their temporal efficacy, or differences in efficacy and safety between opioids with strong versus weak/intermediate μ opioid receptor–binding affinity. To explore these research questions, we conducted a systematic review and meta‐analyses of randomized controlled trials (RCTs) conducted in patients with knee and/or hip OA. Methods We searched Medline, Embase, PubMed Central, and the Cochrane Central Register of Controlled Trials from inception to December 2019 and sought unpublished data. Placebo‐controlled RCTs of oral opioids in patients with knee and/or hip OA were included. Standardized mean differences (SMDs) were calculated for pain and function at 2, 4, 8, and 12 weeks. Subgroup analyses for strong and weak/intermediate opioids were conducted. Meta‐regression was performed to assess the impact of dosage (morphine equivalency) on pain relief. Risk ratios were calculated for safety at the final follow‐up. Results A total of 18 RCTs (9,283 participants) were included. Opioids demonstrated small benefits on pain at each time point, with SMDs ranging from –0.28 (95% confidence interval [95% CI] –0.38, –0.17) to –0.19 (95% CI –0.29, –0.08); similar effects were observed for function. Strong opioids demonstrated consistently inferior efficacy and overall worse safety than weak/intermediate opioids. Meta‐regression revealed that incremental pain relief achieved beyond 20–50‐mg doses was not substantial in the context of increased safety risks. Conclusion Opioids provide minimal relief of OA symptoms within a 12‐week period, and they are known to cause discomfort in a majority of patients. Clinicians and policy makers should reconsider the utility of opioids in the management of OA.

show abstract

Section: Introductionmentioning

confidence: 99%